Skip to content

DM BIOMED DEVELOPMENT

Active Private limited companyfounded 2012active for 14 yearsRue des Montys 53, 4141 SprimontKBO/BCE: BE 0842.657.707
DM BIOMED DEVELOPMENT
Follow ReportCompare

Overview

Lifetime

14 annual accounts with figures on one time axis
peak €73,213 (2013)
€45,196▲ 59.7%
lowest -€11,981 (2023)
€30,532▲ 46.2%
peak €197,070 (2018)
€107,778▲ 39.5%
€16,855▲ 332%
Board1 name since 2012
1 directorMARÉCHAL Daniel Jean Henri Ghislain
Documentsfilings and deeds
24-02-202665 days before the deadline
2025micro format
Gross margin from €28,293 to €45,196Result from €20,879 to €30,532Equity from €77,246 to €107,778Debts from €3,899 to €16,855Investments €3,587Cash from €51,447 to €83,994

Key points

from the 2025 annual accounts

Equity

€107,778 from €197,070 in 2018

Equity fell by 45% in 7 years.

Turnover

≈ €130,000 estimated

The micro format states no turnover.

Investments

€3,587 8.0 × depreciation
20222025

Green is investment, beige is depreciation.

Liquidity

7.21 was 20.71 in 2024

Short-term debts rose from €3,899 to €16,805.

Filings

14 annual accounts since 2012
deadline201520202025

The last five annual accounts were filed 5 to 71 days before the end of the period.

Position in the sector

86.5%

Higher solvency than 84% of companies in head offices and management consultancy. Sector median 55.5% · 39,364 companies.

Checked score

98
Excellent
Financially stronger than 81% of micro companies in head offices and management consultancy (NACE 70)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%

The dashed line is the sector median: 0.1% across 48,570 companies (NACE 70, micro).

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Last 24 months 12-2024: 0.1% 01-2025: 0.1%● unchanged vs 12-2024 02-2025: 0.1%● unchanged vs 01-2025 03-2025: 0.1%● unchanged vs 02-2025 04-2025: 0.1%● unchanged vs 03-2025highest value 05-2025: < 0.1%▼ -0.1 percentage points vs 04-2025 06-2025: < 0.1%● unchanged vs 05-2025 07-2025: < 0.1%● unchanged vs 06-2025 08-2025: < 0.1%● unchanged vs 07-2025 09-2025: < 0.1%● unchanged vs 08-2025 10-2025: < 0.1%● unchanged vs 09-2025 11-2025: < 0.1%● unchanged vs 10-2025 12-2025: < 0.1%● unchanged vs 11-2025 01-2026: < 0.1%● unchanged vs 12-2025 02-2026: < 0.1%● unchanged vs 01-2026 03-2026: < 0.1%● unchanged vs 02-2026 04-2026: < 0.1%● unchanged vs 03-2026 05-2026: < 0.1%● unchanged vs 04-2026 06-2026: < 0.1%● unchanged vs 05-2026 07-2026: < 0.1%● unchanged vs 06-2026 08-2026: < 0.1%● unchanged vs 07-2026 09-2026: < 0.1%● unchanged vs 08-2026 10-2026: < 0.1%● unchanged vs 09-2026lowest value 11-2026: < 0.1%● unchanged vs 10-2026lowest value

Financial strength
Strong

100=equity 86.5% of total assets
98-2short-term debt 13.5% · cash 67.4%
99-1return on assets 24.5%

Score breakdown

lowers risk
Liquidity: current ratio 7.21, cash €83,994
Equity €107,778 (86.5% of total assets)
Sector: Activities of head offices; management consultancy activities (NACE 70)
Size: total assets €124,632
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 70, micro). It does better than 86% of them on solvency, 92% on liquidity, 68% on profitability and 77% on growth.

The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

The probability rests on the annual accounts with balance sheet date 30-09-2025.

Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Comparable companies, two years later

In July 2024, 34,693 companies had the same profile as DM BIOMED DEVELOPMENT has now. Each dot stands for 87 companies, two years later.

95.3%
were still trading
3.9%
stopped another way
0.7%
went bankrupt
  • Micro
  • 10 to 20 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more

That fits the bankruptcy probability of DM BIOMED DEVELOPMENT itself: < 0.1% within 12 months.

Test of the method

The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 3.0% 3.1%
10 5.6% 6.2%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 34,693 companies, not a prediction for DM BIOMED DEVELOPMENT. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit of up to €10,000 on 30-day terms is acceptable

Liquidity is ample, with a current ratio of 7.21 (20.71 in 2024), above the usual 1.5. Short-term debt is 13.5% and cash 67.4% of total assets. 13.5% of the assets are financed with debt and provisions.

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

6 signals, none raises the risk
Six signals.
lowers riskneutral
lowers risk · Liquidity: current ratio 7.21, cash €83,994
NBB · annual accounts
lowers risk · Equity €107,778 (86.5% of total assets)
NBB · annual accounts
lowers risk · Sector: Activities of head offices; management consultancy activities (NACE 70)
KBO
lowers risk · Size: total assets €124,632
Companies of this size fail less often. How much that weighs depends on the rest of the company's profile.
NBB · annual accounts
lowers risk · Growing equity
Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.
NBB · annual accounts 2025
Equity per financial year
19202122232425
2019 to 2025 · latest year €107,778
neutral · Latest accounts filed on time
The financial year that closed on 30-09-2025 was due by 30-04-2026 and was filed on 24-02-2026, 65 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
65 days early
2024
5 days early
2023
71 days early
2022
25 days early
2021
51 days early
2020
81 days early
2019
77 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 7 accounts on average 54 days before the deadline. In the sector (NACE 70), the median for financial year 2024 was 9 days before the deadline, and 32% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The financial year that closed on 30-09-2026 is due by 30-04-2027. Nothing is late today. The company usually files around 10 March (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven months
Where today falls in the filing period
30-09-2026 year end10-11-2026 today30-04-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since 2021.
KBO publications

Board and ownership

MD
MARÉCHAL Daniel Jean Henri Ghislain
Director, since 12-01-2012
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0842657707
Reappointment: MARÉCHAL Daniel Jean Henri Ghislain (director) General meeting of 29-06-2023 · Gazette deed
Incorporation published on 16-01-2012 · Gazette deed
First establishment Rue des Montys 53, Sprimont
All 28 events

Comparable companies

same main activity, similar in size and age
Company
DM BIOMED DEVELOPMENT Sprimont €124,632 €45,196 86.5% -
BISANGA Chaudfontaine €129,147 €42,549 52.6% -
TODA SPRL Awans €112,720 €45,317 37.8% -
RY CONSULTANCY MANAGEMENT AND DEVELOPMENT Liège €105,747 €42,740 66.5% -
TP SQUARE CONSULTING Dison €142,316 €39,854 64.4% -
JPS Business Consulting Waimes €134,466 €37,517 81.6% 0.6
OH SERVICES Woluwe-Saint-Pierre €123,969 €43,874 67.5% 0.1

These companies have the same main activity as DM BIOMED DEVELOPMENT: business and other management consultancy (NACE 70200). They are comparable in size and age: total assets between €106,000 and €142,000, founded between 2010 and 2012.

Official details

Source: KBO
Status
Active since 12-01-2012Normal situation
Activity
Business and other management consultancyNACE 70200
Establishment unit
2.206.672.8934141 Sprimont, since 12-01-2012
Financial year end
30 September
Peppol
Reachable since 15-09-2025
Company details

Annual accounts to 30-09-2025

€45,196▲ 59.7%
€30,532▲ 46.2%
€107,778▲ 39.5%
€124,632▲ 53.6%
Filing
Filed on 24-02-2026, 65 days before the end of the filing period
Financials

Insights on DM BIOMED DEVELOPMENT

DM BIOMED DEVELOPMENT files the micro format. That format states no turnover. The gross margin fell from €67,517 in 2012 to €45,196 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette.

Financials

Annual accounts 2025

micro format, filed on 24-02-2026, 65 days before the deadline
€45,196
▲ 59.7%
€44,039
▲ 64.9%
€44,487
▲ 61.2%
€30,980
▲ 42.3%
86.5%
▼ 8.7 percentage points
7.21
▼ 13.50

Turnover and EBIT margin are not published. The micro format does not require them. The turnover shown is an estimate from the gross margin.

Turnover ≈ €130,000. Estimated: probably between €79,000 and €180,000.

Money flows

no detail for 2025

Balance sheet

balance sheet total €124,632 on 30-09-2025
What the company ownsHow it is paid for

in euro

in euro

Position in the sector

Compare with sector

86.5%

Higher than 85% of 39,364 companies in 2025.

7.21

Higher than 85% of 38,048 companies in 2025.

24.5%

Higher than 64% of 38,520 companies in 2025.

DM BIOMED DEVELOPMENT Middle half of the sector 80% of the sector Micro accounts in head offices and management consultancy (NACE 70)

Net result: middle half · Equity: middle half · Balance sheet total: middle half · Working capital: middle half

Filed annual accounts

as filed with the National Bank, click a year to choose it
Line Trend20252024202320222021202020192018201720162015201420132012
Balance sheet: assets
20/58 124,63281,14460,665131,528140,496109,33390,508209,815211,953178,684164,410135,219112,24695,242
21/28 3,5464061,2942,9793,1263,7696,8377,1336,1367,3964,3617,17710,044261
22/27 3,5464061,2942,9793,1263,7696,8377,1336,1367,3964,3617,17710,044261
24 963536711,289---1,219---6351,322261
26 2,5833546231,6913,1263,7696,8375,9146,1367,3964,3616,5428,722-
29/58 121,08680,73859,372128,549137,370105,56483,671202,682205,817171,288160,049128,042102,20194,981
3 11,4697,92413,17212,54010,97210,41210,0769,8469,910-----
30/36 11,4697,92413,17212,54010,97210,41210,0769,8469,910-----
40/41 22,87616,47817,12511,11720,94632,14316,73217,54711,61723,39817,78220,12419,45716,453
40 16,02712,1589,4716,21215,59331,20216,73112,89511,61714,33016,82520,12412,61913,004
41 6,8504,3217,6544,9055,35394114,652-9,068957-6,8373,450
50/53 -------140,68290,68290,68290,682---
54/58 83,99451,44721,50894,28692,01348,54056,15432,85092,36555,59849,170106,80780,65978,201
490/1 2,7474,8887,56710,60513,44014,4697091,7561,2421,6092,4141,1112,086327
Balance sheet: equity and liabilities
10/49 124,63281,14460,665131,528140,496109,33390,508209,815211,953178,684164,410135,219112,24695,242
10/15 107,77877,24656,36768,348106,699101,09168,811197,070185,061160,057144,05397,83518,45317,458
10/11 62,12462,12462,12462,12462,12462,12462,12462,12462,12462,12462,12462,12415,00015,000
100 ------62,12462,12462,12462,12462,12462,12418,60018,600
101 ------------3,6003,600
13 45,65415,1226,2126,2126,2126,2126,2126,2126,2126,2126,2123,4731,8601,500
130/1 ---6,2126,2126,212--------
130 ------6,2126,2126,2126,2126,2123,4731,8601,500
1311 ---6,2126,2126,212--------
133 45,65415,1226,212-----------
14 ---11,9701138,36332,754475128,734116,72591,72075,71632,2381,593958
17/49 16,8553,8994,29963,18033,7978,24221,69712,74526,89218,62820,35737,38493,79377,784
42/48 16,8053,8994,11463,18033,7978,14321,69712,74526,89218,62820,35737,38493,77177,681
44 4,7141,3331,7401,4831,0684979173,46091453375314,053116188
440/4 4,7141,3331,7401,4831,0684979173,46091453375314,053116188
45 12,0902,3622,3743,6972,7297,6462,5665,34015,4162,95012,16720,85251,65538,493
450/3 12,0902,3622,3743,6972,7297,6462,5665,34015,4162,95012,16720,85251,65535,268
454/9 -------------3,225
47/48 -204-58,00030,000-18,2143,94510,56115,1457,4372,47842,00039,000
492/3 50-185--100------22103
Income statement
70 ------------152,724-
9900 45,19628,293-7,53332,06049,75347,14542,67421,46741,07626,19370,94353,85473,21367,517
60/61 ------------88,204-
630 4478871,6862,0001,9913,0684,2873,4894,0413,4852,8162,8683,024157
640/8 7106961,1523219027916336046496241,3895541,1831,751
9901 44,03926,709-10,37029,73946,86043,28637,75517,37536,38722,08466,73950,43269,00665,610
75/76B 3351301573193014221,5301,4011,2802,437204766517
75 3351301573193014221,5301,4011,2802,437204766517
65/66B 1,2771,5181,5201,6231,9171,19911,6371,2221,3442,1472,9722,7852,3811,455
65 1,2771,5181,5201,6231,9171,19911,6371,2221,3442,1472,9722,7852,3811,455
9903 43,09825,321-11,73328,43545,24342,12926,12117,68236,44421,21766,20347,85167,39164,671
67/77 12,5664,4432488,7879,6359,8508,6465,67311,4395,21319,98515,59324,39623,214
9904 30,53220,879-11,98119,64935,60832,28017,47512,00925,00516,00446,21832,25842,99541,458
9905 30,53220,879-11,98119,64935,60832,28017,47512,00925,00516,00446,21832,25842,99541,458
Appropriation of the result
9906 30,5328,909-11,97058,01168,36332,754146,209128,734116,72591,72078,45633,85143,95341,458
14P --11,9701138,363----------
691/2 30,5328,909--------2,7391,6133601,500
6920 ----------2,7391,6133601,500
6921 30,5328,909------------
694/7 ---58,00030,000-145,734-----42,00039,000
694 ---58,00030,000-145,734-----42,00039,000
Document PDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDF

The notes to these accounts have 6 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the filed accounts (PDF).

Source: Annual accounts 2025 (PDF), filed on 24-02-2026.

Download as CSV

Filings

each dot is a set of accounts, on the day it reached the National Bank
Financial year Type Filed Reference Document
30-09-2025 micro format 24-02-2026 2026-00044607 PDF
30-09-2024 micro format 25-04-2025 2025-00082977 PDF
30-09-2023 micro format 19-02-2024 2024-00032288 PDF
30-09-2022 micro format 05-04-2023 2023-00057115 PDF
30-09-2021 micro format 10-03-2022 2022-07500157 PDF
30-09-2020 micro format 08-02-2021 2021-05000336 PDF
30-09-2019 micro format 13-02-2020 2020-05100106 PDF
30-09-2018 full format 21-02-2019 2019-05600307 PDF
30-09-2017 full format 09-02-2018 2018-04800041 PDF
30-09-2016 full format 02-03-2017 2017-05700532 PDF
30-09-2015 full format 04-02-2016 2016-03900090 PDF
30-09-2014 full format 11-02-2015 2015-04000346 PDF
30-09-2013 full format 19-02-2014 2014-04200330 PDF
30-09-2012 full format 08-04-2013 2013-08600594 PDF

Key figures and ratios

per financial year, computed from the annual accounts
Line Trend20252024202320222021202020192018201720162015201420132012
44,48727,597-8,68531,74048,85146,35342,04220,86440,42725,56869,55453,29972,03065,766
30,98021,766-10,29521,64937,59935,34721,76215,49829,04519,48849,03335,12646,01941,614
3,587001,8541,34703,9914,4862,7806,520012,29012,807418
32,54629,940-72,7782,27443,473-7,61423,304-59,51536,7676,427-57,63626,1482,458-
104,28276,83955,25765,368103,57397,42161,974189,937178,925152,660139,69290,6588,43117,300
------------45.2%-
86.5%95.2%92.9%52.0%75.9%92.5%76.0%93.9%87.3%89.6%87.6%72.4%16.4%18.3%
7.2120.7114.432.034.0612.963.8615.907.659.207.863.431.091.22
6.5218.6811.231.843.7411.693.3915.137.299.207.863.431.091.22
0.160.050.080.920.320.080.320.060.150.120.140.385.084.46
28.3%27.0%-21.3%28.7%33.4%31.9%25.4%6.1%13.5%10.0%32.1%33.0%233.0%237.5%
24.5%25.7%-19.7%14.9%25.3%29.5%19.3%5.7%11.8%9.0%28.1%23.9%38.3%43.5%
34.8418.18-5.7119.56----------
------------30 days-
------------0 days-

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Investments

fixed assets acquired
Item30-09-202530-09-202430-09-202330-09-2022
Tangible fixed assets€3,587--€1,854
€447€887€1,686€2,000

Source: notes to the 2022 to 2025 annual accounts (statement of fixed assets)

Insights on DM BIOMED DEVELOPMENT

The operating result for 2025 is 65% higher than in 2024 and the highest since 2021. It is the second rise in a row, after the fall in 2023.

Debt's share of the balance-sheet total rises from 4.8% to 13.5%. Equity and debt are higher.

Board & ownership

Board

1 director
MARÉCHAL Daniel Jean Henri Ghislain
Director (not named in the articles)
since 12-01-2012 term without a fixed end
listed in the 2025 annual accounts, filed on 24-02-2026

Office holders in the KBO →

Mandates through the years

1 name, the dashed line is today
MARÉCHAL Daniel Jean Henri Ghislain
Director (not named in the articles)
Board
Mandates as a list
  • MARÉCHAL Daniel Jean Henri Ghislain
    • Director (not named in the articles), from 12-01-2012 to date

See the board, name and registered office on a given date →

Control

See the annual accounts at the National Bank and the publications in the Belgian Official Gazette.

Capital

Contribution
€62,124
Source
2025 annual accounts

Articles of association

deed of 07-07-2023 (in French)
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
Board ruleThese rules set how the board is made up, meets and takes decisions.
At least 1 director
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
“L’organe d’administration détermine s’ils agissent seul ou conjointement. Les délégués à la gestion journalière peuvent, en ce qui concerne…”

Network & group

No group

DM BIOMED DEVELOPMENT has no parent and no holdings in its annual accounts. MARÉCHAL Daniel Jean Henri Ghislain is the only director. DM BIOMED DEVELOPMENT shares no director with another company.

Timeline

Timeline

28 events since 2012

Deadline for the 2026 accounts: 30-04-2027

2026
Annual accounts 2025 filed PDFmicro format · 65 days before the deadline
2025
Registered in the Peppol Directory Reachable for e-invoices through 0208:0842657707
Annual accounts 2024 filed PDFmicro format · 5 days before the deadline
2024
Back to profit net €20,879 The net result is €20,879, after one loss-making year.
Annual accounts 2023 filed PDFmicro format · 71 days before the deadline
2023
Weakest financial year net -€11,981 The net result drops to -€11,981, the lowest from 2012 to 2025. It recovers the following year.
Liquidity more than 7 times current ratio 14.43 The current ratio rises from 2.03 to 14.43. Short-term debt falls from €63,180 to €4,114.
Reappointment: MARÉCHAL Daniel Jean Henri Ghislain (director)General meeting of 29-06-20233 points ▸
  • General meeting, 29-06-2023
  • Director reappointment, MARÉCHAL Daniel Jean Henri Ghislain (director (not named in the articles))
  • Registered office clause, rue des Montys 53, 4141 Louveigné (Sprimont)
  • The deed holds 4 more points.

Open the deed in the Belgian Official Gazette

Annual accounts 2022 filed PDFmicro format · 25 days before the deadline
2022
Annual accounts 2021 filed PDFmicro format · 51 days before the deadline
2021
Annual accounts 2020 filed PDFmicro format · 81 days before the deadline
2020
Liquidity more than triples current ratio 12.96 The current ratio rises from 3.86 to 12.96. Short-term debt falls from €21,697 to €8,143.
Annual accounts 2019 filed PDFmicro format · 77 days before the deadline
2019
Annual accounts 2018 filed PDFfull format · 68 days before the deadline
2018
Liquidity more than doubled current ratio 15.90 The current ratio rises from 7.65 to 15.90. Short-term debt falls from €26,892 to €12,745.
Annual accounts 2017 filed PDFfull format · 80 days before the deadline
2017
Annual accounts 2016 filed PDFfull format · 59 days before the deadline
2016
Equity above €150,000 equity €160,057 ▲11.1% With a profit in every financial year since 2012, equity grows to €160,057.
Annual accounts 2015 filed PDFfull format · 86 days before the deadline
2015
Highest result from 2012 to 2025 net €46,218 ▲43.3% The net result of €46,218 is the highest of those years.
Liquidity more than doubled current ratio 7.86 The current ratio rises from 3.43 to 7.86. Short-term debt falls from €37,384 to €20,357.
Equity above €100,000 equity €144,053 ▲47.2% With a profit in every financial year since 2012, equity grows to €144,053.
Annual accounts 2014 filed PDFfull format · 78 days before the deadline
2014
Liquidity more than triples current ratio 3.43 The current ratio rises from 1.09 to 3.43. Short-term debt falls from €93,771 to €37,384.
Annual accounts 2013 filed PDFfull format · 70 days before the deadline
2013
Annual accounts 2012 filed PDFfull format · 22 days before the deadline
2012
Incorporation PDFpublished on 16-01-2012
First establishment Rue des Montys 53, Sprimont

Financial milestones sit on the financial year-end date, not the filing date.

Sources: Publications in the Belgian Official GazetteFilings with the National Bank

History

On 12 January 2012, DM BIOMED DEVELOPMENT was incorporated.1 Total assets went from €90,508 in 2019 to €124,632 in 2025.2

  1. 1KBO register
  2. 2National Bank, annual accounts 2019 and 2025

Company details

Identity

Enterprise number
0842.657.707
VAT number
BE 0842.657.707
Peppol ID
0208:0842657707
Other Peppol ID
9925:BE0842657707
Legal form
Private limited company
Status
Active, normal situation
Founded
12-01-2012
Financial year
ends on 30 September
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
“L’organe d’administration détermine s’ils agissent seul ou conjointement. Les délégués à la gestion journalière peuvent, en ce qui concerne…”
deed of 07-07-2023 (in French)
Peppol
Reachable since 15-09-2025Follow this company and you will hear the next morning if it leaves the Peppol register.
Name
DM BIOMED DEVELOPMENT in French
Entity type
Legal entity
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
deed of 07-07-2023 (in French)

Activities

NACEBEL 2025
70200 Business and other management consultancy main activity
Codes under NACEBEL 2008
70220 Business consulting main activity
PurposeThe purpose describes the activities the company may carry out under its articles.
“1. la prestation de services de tous types en rapport avec le biomédical et la biotechnologie,dans le domaine de la consultance,de…”
3 activities
  1. 1. la prestation de services de tous types en rapport avec le biomédical et la biotechnologie,dans le domaine de la consultance,de l’analyse,de l’accompagnement psychosocial,ainsi que de la formation et de l’animation d’équipes,de groupes et de personnes dans leurs projets de création,d’évolution ou de développement ;
  2. 2. la prestation de services,de conseils et de formations en matière de gestion et organisation d’entreprises,en gestion de ressources humaines,en marketing et en environnement,sous forme d’études,d’expertise,de conseils,de marketing,de management ou d’administration ;
  3. 3. la prestation de conseils,la consultance au sens large et la formation en matière de communication.
deed of 07-07-2023 (in French)

Registered office and establishments

1 establishment
Establishment Since Unit number
Rue des Montys 53 registered office 4141 Sprimont 12-01-2012 2.206.672.893

Buildings and parcels at the address

Ground area
3,077 m²
Buildings
107 m²
Volume, LiDAR
638 m³
Tallest building
7.3 m
Buildings to scale, each on its own parcel
107 m², 7.3 m 107 m², 7.3 m

Location

registered office establishment The establishment unit on the map

Parcels

Cadastral parcelArea Buildings Height / floors
62067F0093/00M0003,077 m² 1 · 107 m² 7.3 m · 2

We would like to set cookies. That happens only with your consent. What we measure